Brokerages Set Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Target Price at $37.70

Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) have received a consensus rating of “Buy” from the thirteen brokerages that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, ten have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $37.70.

Several analysts have recently commented on the company. Truist Financial set a $30.00 price objective on Centessa Pharmaceuticals in a report on Wednesday, November 5th. B. Riley upped their target price on Centessa Pharmaceuticals from $33.00 to $42.00 and gave the company a “buy” rating in a research report on Monday, December 1st. Lifesci Capital raised Centessa Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, September 3rd. Stephens initiated coverage on Centessa Pharmaceuticals in a research note on Tuesday, October 28th. They set an “overweight” rating and a $35.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, October 8th.

Insiders Place Their Bets

In related news, insider Mario Alberto Accardi sold 10,000 shares of the stock in a transaction on Monday, December 8th. The shares were sold at an average price of $30.00, for a total transaction of $300,000.00. Following the sale, the insider directly owned 178,801 shares of the company’s stock, valued at approximately $5,364,030. This represents a 5.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CTO Tia L. Bush sold 40,000 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $26.00, for a total value of $1,040,000.00. Following the sale, the chief technology officer owned 121,503 shares in the company, valued at $3,159,078. This trade represents a 24.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 99,000 shares of company stock valued at $2,514,460. 7.09% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of CNTA. China Universal Asset Management Co. Ltd. lifted its stake in shares of Centessa Pharmaceuticals by 4.8% in the second quarter. China Universal Asset Management Co. Ltd. now owns 19,181 shares of the company’s stock worth $252,000 after buying an additional 870 shares in the last quarter. HighMark Wealth Management LLC raised its holdings in Centessa Pharmaceuticals by 0.6% in the 2nd quarter. HighMark Wealth Management LLC now owns 237,285 shares of the company’s stock valued at $3,118,000 after acquiring an additional 1,500 shares during the last quarter. HighVista Strategies LLC lifted its stake in Centessa Pharmaceuticals by 4.3% in the 2nd quarter. HighVista Strategies LLC now owns 40,684 shares of the company’s stock worth $535,000 after purchasing an additional 1,664 shares in the last quarter. Trexquant Investment LP boosted its holdings in shares of Centessa Pharmaceuticals by 1.1% during the 1st quarter. Trexquant Investment LP now owns 263,994 shares of the company’s stock worth $3,796,000 after purchasing an additional 2,810 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its position in shares of Centessa Pharmaceuticals by 15,209.5% in the first quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company’s stock valued at $46,000 after purchasing an additional 3,194 shares in the last quarter. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Trading Down 1.4%

CNTA opened at $26.15 on Friday. Centessa Pharmaceuticals has a 52 week low of $9.60 and a 52 week high of $30.58. The company has a market capitalization of $3.52 billion, a P/E ratio of -14.29 and a beta of 1.55. The stock’s fifty day moving average is $25.63 and its two-hundred day moving average is $19.88. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.02). Analysts forecast that Centessa Pharmaceuticals will post -1.6 earnings per share for the current year.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.